Long-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. It has recently witnessed a daily gain of 0.97%, juxtaposed with a three-month change of -48.16%. However, fresh insights from the GF Score hint at potential headwinds. Notably, its diminished rankings in financial strength, growth, and valuation suggest that the company might not live up to its historical performance. Join us as we dive deep into these pivotal metrics to unravel the evolving narrative of Moderna Inc.
What Is the GF Score?
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with a lower GF Score. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
- Financial strength rank: 8/10
- Profitability rank: 3/10
- Growth rank: 3/10
- GF Value rank: 1/10
- Momentum rank: 5/10
Based on the above method, GuruFocus assigned Moderna Inc the GF Score of 58 out of 100, which signals poor future outperformance potential.
Understanding Moderna Inc's Business
Moderna Inc, a commercial-stage biotech founded in 2010 and publicly listed in December 2018, has rapidly validated its mRNA technology with its COVID-19 vaccine, authorized in the United States in December 2020. With a market cap of $29.73 billion and sales of $4.99 billion, Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. However, its operating margin stands at -92.92%, indicating significant challenges.
Profitability Breakdown
Moderna Inc's low Profitability rank can also raise warning signals. With a Piotroski F-Score of 2, Moderna Inc's financial health appears concerning. This score, rooted in Joseph Piotroski's nine-point scale, evaluates a firm's profitability, liquidity, and operating efficiency. Given its rating, Moderna Inc might be facing challenges in these areas.
Growth Prospects
A lack of significant growth is another area where Moderna Inc seems to falter, as evidenced by the company's low Growth rank.
Next Steps
Considering the company's financial strength, profitability, and growth metrics, the GF Score highlights the firm's unparalleled position for potential underperformance. Investors should be cautious and consider these factors when evaluating Moderna Inc's future prospects.
GuruFocus Premium members can find more companies with strong GF Scores using the following screener link: GF Score Screen
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
